The FDA will study the link between users’ perceptions of drug efficacy and the name of the drug itself. Zachary Brennan writes, “The study will compare five target names that may just suggest a medical condition or vary in terms of how the name portrays a drug’s efficacy, with one name that explicitly suggests strong efficacy (CuresFlux) and one that is more neutral (Zerpexin). Participants will answer questions about the names, before and after they have been told what each drug’s indication is.”
Read more about this study and the role of names in drug perception on Endpoints News.